Syndax Pharmaceuticals, Inc.
SNDX
$19.84
$0.763.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 222.65% | 397.28% | 628.88% | 597.19% | 2,133.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 222.65% | 397.28% | 628.88% | 597.19% | 2,133.71% |
| Cost of Revenue | 3.45% | 6.52% | 9.60% | 8.44% | 32.10% |
| Gross Profit | 89.09% | 76.91% | 57.42% | 35.32% | 5.46% |
| SG&A Expenses | 13.24% | 26.89% | 48.65% | 58.01% | 66.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.06% | 13.83% | 22.59% | 24.02% | 43.05% |
| Operating Income | 42.69% | 34.96% | 19.68% | 4.53% | -17.64% |
| Income Before Tax | 34.10% | 26.56% | 10.46% | -4.89% | -26.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.10% | 26.56% | 10.46% | -4.89% | -26.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.10% | 26.56% | 10.46% | -4.89% | -26.85% |
| EBIT | 42.69% | 34.96% | 19.68% | 4.53% | -17.64% |
| EBITDA | 42.69% | 34.96% | 19.68% | 4.53% | -17.65% |
| EPS Basic | 35.43% | 27.68% | 11.63% | 0.45% | -15.38% |
| Normalized Basic EPS | 35.43% | 27.68% | 11.63% | 0.45% | -15.38% |
| EPS Diluted | 35.43% | 27.72% | 11.68% | 0.64% | -15.15% |
| Normalized Diluted EPS | 35.43% | 27.68% | 11.63% | 0.45% | -15.38% |
| Average Basic Shares Outstanding | 2.18% | 1.72% | 1.40% | 5.02% | 9.87% |
| Average Diluted Shares Outstanding | 2.18% | 1.72% | 1.40% | 5.02% | 9.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |